Elevated bile acids in newborns with Biliary Atresia (BA)

Area of Science:

• Neonatal Hepatology
• Biochemical Diagnostics
• Infant Gastroenterology

Background:

• Biliary Atresia (BA) is a severe infantile liver disease caused by bile duct inflammation.
• Early diagnosis and intervention, like the Kasai operation, significantly improve patient outcomes.
• Developing effective early screening methods for BA is crucial.

Purpose of the Study:

• To investigate the potential of primary bile acids as biomarkers for early Biliary Atresia detection.
• To evaluate taurocholate (TC) levels in newborns for discriminating BA from other conditions.

Main Methods:

• High-performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS) was used.
• Primary bile acid content was measured in dried blood spots from BA infants, neonatal jaundice infants, and comparison infants.
• Receiver operating characteristic (ROC) curve analysis was performed to assess diagnostic accuracy.

Main Results:

• Taurocholate (TC) levels were significantly higher in BA infants compared to both neonatal jaundice and comparison infants (p<0.05).
• ROC analysis indicated TC has good discriminatory power for BA (AUC=0.82).
• Total bile acid concentrations were also significantly elevated in BA infants compared to controls (p=0.0162).

Conclusions:

• Elevated bile acids, particularly TC, in the immediate newborn period suggest BA presentation.
• Taurocholate shows promise as a potential biomarker for newborn screening of Biliary Atresia.
• Further validation is needed to establish TC as a reliable screening marker.